Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.
